AstraZeneca's Head and Neck Cancer Drug Fails to Meet Phase 3 Trial Main, Secondary Goal
07:08 AM EST, 02/05/2021 (MT Newswires) -- AstraZeneca's (AZN) Imfinzi failed to meet the late-stage Kestrel trial's main goal of increasing overall survival in certain cancer patients more than standard of care treatment.
The British drug maker said the therapy failed to beat chemotherapy plus cetuximab in treating recurring head and neck squamous cell carcinoma in patients whose tumors showed high levels of the PD-L1 protein.
Imfinzi, also known as durvalumab, did not improve patient survival when combined with tremelimumab either, thereby failing the study's secondary goal as well, AstraZeneca said.
Price: 50.22, Change: -0.14, Percent Change: -0.28